ONCOSIGNATURE
Live / Registered — Registered — partial invalidation of extension of protection (as of 10 Feb 2026)
What this means for you
Registered since 09 Apr 2019. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79223972
- Registration number
- 5718472
- Mark type
- Design + words
- Filed
- 22 Sept 2017
- Published for opposition
- 22 Jan 2019
- Registered
- 09 Apr 2019
- Attorney of record
- Sara M. Bauer
Goods and services
- Class 005 — Pharmaceuticals: [ Pharmaceutical preparations for use in oncology, specifically the prevention, alleviation and treatment of cancer and precancerous diseases and benign tumors; medical preparations for use in oncology, specifically the prevention, alleviation and treatment of cancer and precancerous diseases and benign tumors; veterinary pharmaceutical preparations for use in oncology, specifically the prevention, alleviation and treatment of cancer and precancerous diseases and benign tumors; pharmaceutical and medical preparations for treatment, prevention and alleviation of cancer; pharmaceutical and medical preparations for the prediction of drug treatment efficacy; pharmaceutical and medical preparations for prognosis related to cancer; biological preparations for medical and veterinary purposes, namely, for use in oncology, specifically the prevention, alleviation and treatment of cancer and precancerous diseases and benign tumors; diagnostic kits consisting primarily of monoclonal antibodies for use in disease testing, specifically in oncology and premalignant disorders and benign tumors; chemical preparations for therapeutic use, namely, for pharmaceutical or medical purposes, namely, for use in oncology, specifically the prevention, alleviation and treatment of cancer and precancerous diseases and benign tumors; reagents for medical use, namely, for medical diagnosis, drug-tailored efficacy prediction and/or analysis; clinical medical reagents; diagnostic preparations for medical and veterinary purposes; diagnostic test materials for medical use in the field of oncology in the form of a clinical biomarker signature assay on biopsy or other patient sample material for measuring biomarkers reflective of disease-driving processes that the drug inhibits and does not inhibit to predict treatment efficacy within oncology; diagnostic preparations for medical use; diagnostic biomarker reagents for medical purposes; companion diagnostic biomarker reagents for medical purposes ]
- Class 042 — Scientific and technological services: Scientific and technological research and consultation services, namely, in the medical, pharmaceutical, and scientific research fields of drug-tailored, efficacy-predictive biomarkers, pharmacodynamic biomarkers, drug repurposing, and identification of rational drug combinations; industrial analysis and research services, namely, industrial research in the field of oncology; basic medical research and medical clinical research, hereunder for development of therapeutics; drug discovery services; consultancy in the field of pharmaceutical research and development; medical and scientific research related to cancer and cancer therapy, including research related to treatment, prevention and alleviation of cancer; pharmaceutical research services related to prediction of drug treatment efficacy; medical research services related to cancer diagnosis, cancer prognosis and drug-tailored efficacy prediction; medical research, namely, analysis related to cancer diagnosis, cancer prognosis and drug-tailored efficacy prediction
Owner
- Acrivon Therapeutics Inc., Watertown Massachusetts, US
- OncoSignature AB, Lund, SE
- OncoSignature AB, Lund, SE
- OncoSignature AB, Lund, SE
Prosecution history
- 10 Feb 2026 — NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
- 10 Feb 2026 — REGISTERED - PARTIAL SEC 71 ACCEPTED
- 09 Feb 2026 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 07 Oct 2025 — TEAS SECTION 71 RECEIVED
- 18 Apr 2025 — LIMITATION OF GOODS RECEIVED FROM IB
- 12 Mar 2025 — TEAS VOLUNTARY AMENDMENT RECEIVED
- 04 Oct 2024 — NEW REPRESENTATIVE AT IB RECEIVED
- 09 Apr 2024 — COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
- 26 Feb 2022 — CHANGE OF OWNER RECEIVED FROM IB
- 13 Jul 2021 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 13 Jul 2021 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 13 Jul 2021 — TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
- 13 Jul 2021 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 13 Jul 2021 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 13 Jul 2021 — TEAS CHANGE OF OWNER ADDRESS RECEIVED